A study of ACER-001 for the treatment of Maple Syrup Urine Disease (MSUD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jul 2022 According to an Acer Therapeutics media release, the company announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA); this trial is planned to initiate in the first half of 2023 subject to IND clearance and available capital
16 May 2022 According to an Acer Therapeutics media release, he company expect to submit an Investigational New Drug (IND) application by the end of Q2 2022.
02 Mar 2022 According to an Acer Therapeutics media release, H2 2022, Acer plans to initiate in H2 2022 a clinical study evaluating ACER-001 in MSUD, subject to additional capital

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com